Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO5711.1 | Streptomyces libani ferm 10638 | Subspecies | Streptomycetaceae | Bacteria | StreptomeDB* |
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT2 | Others | Unspecified | IC50 | = | 12410 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | IC50 | = | 28550 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | EC50 | = | 16320 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | IC50 | = | 1735 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | 1995.3 | nM | PubChem BioAssay data set | ||
NPT2971 | Individual Protein | DNA dC->dU-editing enzyme APOBEC-3F | Homo sapiens | Potency | 35481.3 | nM | PubChem BioAssay data set | |
NPT10 | Individual Protein | Geminin | Homo sapiens | Potency | 18356.4 | nM | PubChem BioAssay data set | |
NPT477 | Individual Protein | DNA dC->dU-editing enzyme APOBEC-3G | Homo sapiens | Potency | 2511.9 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | 501.2 | nM | PubChem BioAssay data set | ||
NPT478 | Individual Protein | Ataxin-2 | Homo sapiens | Potency | 39810.7 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | 18356.4 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 23109.3 | nM | PubChem BioAssay data set | ||
NPT861 | Individual Protein | Isocitrate dehydrogenase [NADP] cytoplasmic | Homo sapiens | Potency | 20596.2 | nM | PubChem BioAssay data set | |
NPT444 | Individual Protein | Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens | Potency | 35481.3 | nM | PubChem BioAssay data set | |
NPT535 | Individual Protein | Parathyroid hormone receptor | Homo sapiens | Potency | 7943.3 | nM | PubChem BioAssay data set |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC315063 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.9167 | High Similarity | NPC43246 |
0.9167 | High Similarity | NPC89051 |
0.881 | High Similarity | NPC106780 |
0.8462 | Intermediate Similarity | NPC17892 |
0.8462 | Intermediate Similarity | NPC36985 |
0.837 | Intermediate Similarity | NPC283698 |
0.837 | Intermediate Similarity | NPC73765 |
0.8202 | Intermediate Similarity | NPC210456 |
0.8202 | Intermediate Similarity | NPC163352 |
0.8132 | Intermediate Similarity | NPC324390 |
0.8095 | Intermediate Similarity | NPC329077 |
0.8043 | Intermediate Similarity | NPC320249 |
0.8043 | Intermediate Similarity | NPC322594 |
0.7865 | Intermediate Similarity | NPC71339 |
0.7865 | Intermediate Similarity | NPC112842 |
0.7802 | Intermediate Similarity | NPC62927 |
0.7802 | Intermediate Similarity | NPC190334 |
0.7604 | Intermediate Similarity | NPC317639 |
0.7549 | Intermediate Similarity | NPC329277 |
0.7473 | Intermediate Similarity | NPC229249 |
0.7447 | Intermediate Similarity | NPC171116 |
0.7404 | Intermediate Similarity | NPC155087 |
0.7404 | Intermediate Similarity | NPC149843 |
0.7386 | Intermediate Similarity | NPC325902 |
0.7292 | Intermediate Similarity | NPC327344 |
0.7245 | Intermediate Similarity | NPC226769 |
0.7245 | Intermediate Similarity | NPC6166 |
0.7245 | Intermediate Similarity | NPC280946 |
0.7172 | Intermediate Similarity | NPC120887 |
0.7172 | Intermediate Similarity | NPC90240 |
0.7143 | Intermediate Similarity | NPC318166 |
0.7143 | Intermediate Similarity | NPC324516 |
0.71 | Intermediate Similarity | NPC328779 |
0.6979 | Remote Similarity | NPC328806 |
0.6961 | Remote Similarity | NPC328914 |
0.6882 | Remote Similarity | NPC319753 |
0.6842 | Remote Similarity | NPC325723 |
0.68 | Remote Similarity | NPC329384 |
0.6742 | Remote Similarity | NPC315806 |
0.6471 | Remote Similarity | NPC284651 |
0.6417 | Remote Similarity | NPC315058 |
0.64 | Remote Similarity | NPC109188 |
0.6372 | Remote Similarity | NPC478024 |
0.626 | Remote Similarity | NPC313962 |
0.5984 | Remote Similarity | NPC325750 |
0.5895 | Remote Similarity | NPC470782 |
0.5851 | Remote Similarity | NPC126186 |
0.5798 | Remote Similarity | NPC313813 |
0.5729 | Remote Similarity | NPC469972 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC315063 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.9167 | High Similarity | NPD9580 | Clinical (unspecified phase) |
0.9167 | High Similarity | NPD9581 | Clinical (unspecified phase) |
0.8605 | High Similarity | NPD9557 | Clinical (unspecified phase) |
0.8506 | High Similarity | NPD9562 | Discovery |
0.837 | Intermediate Similarity | NPD9639 | Clinical (unspecified phase) |
0.814 | Intermediate Similarity | NPD9556 | Approved |
0.8132 | Intermediate Similarity | NPD9565 | Discontinued |
0.8046 | Intermediate Similarity | NPD9561 | Approved |
0.8046 | Intermediate Similarity | NPD9560 | Approved |
0.8022 | Intermediate Similarity | NPD755 | Phase 3 |
0.7957 | Intermediate Similarity | NPD1686 | Approved |
0.7955 | Intermediate Similarity | NPD9546 | Phase 2 |
0.7955 | Intermediate Similarity | NPD9559 | Phase 1 |
0.7931 | Intermediate Similarity | NPD9558 | Phase 3 |
0.7865 | Intermediate Similarity | NPD9533 | Phase 2 |
0.7865 | Intermediate Similarity | NPD280 | Approved |
0.7812 | Intermediate Similarity | NPD502 | Approved |
0.7802 | Intermediate Similarity | NPD9603 | Phase 3 |
0.7802 | Intermediate Similarity | NPD241 | Discontinued |
0.7802 | Intermediate Similarity | NPD9602 | Phase 3 |
0.7802 | Intermediate Similarity | NPD9604 | Approved |
0.7708 | Intermediate Similarity | NPD762 | Discontinued |
0.7692 | Intermediate Similarity | NPD240 | Phase 3 |
0.7692 | Intermediate Similarity | NPD170 | Approved |
0.7624 | Intermediate Similarity | NPD3128 | Phase 3 |
0.7556 | Intermediate Similarity | NPD9529 | Phase 1 |
0.7549 | Intermediate Similarity | NPD3129 | Phase 3 |
0.75 | Intermediate Similarity | NPD501 | Phase 1 |
0.7475 | Intermediate Similarity | NPD223 | Clinical (unspecified phase) |
0.7474 | Intermediate Similarity | NPD9585 | Discontinued |
0.7474 | Intermediate Similarity | NPD6943 | Clinical (unspecified phase) |
0.7473 | Intermediate Similarity | NPD9601 | Approved |
0.7473 | Intermediate Similarity | NPD238 | Clinical (unspecified phase) |
0.7473 | Intermediate Similarity | NPD239 | Phase 2 |
0.7447 | Intermediate Similarity | NPD841 | Approved |
0.7419 | Intermediate Similarity | NPD1760 | Approved |
0.7292 | Intermediate Similarity | NPD251 | Approved |
0.7255 | Intermediate Similarity | NPD1061 | Clinical (unspecified phase) |
0.7172 | Intermediate Similarity | NPD514 | Clinical (unspecified phase) |
0.7158 | Intermediate Similarity | NPD9554 | Approved |
0.7158 | Intermediate Similarity | NPD9553 | Approved |
0.7158 | Intermediate Similarity | NPD301 | Discontinued |
0.7157 | Intermediate Similarity | NPD7651 | Approved |
0.7143 | Intermediate Similarity | NPD9600 | Approved |
0.7041 | Intermediate Similarity | NPD279 | Clinical (unspecified phase) |
0.701 | Intermediate Similarity | NPD267 | Discontinued |
0.7 | Intermediate Similarity | NPD3138 | Phase 3 |
0.6989 | Remote Similarity | NPD9572 | Clinical (unspecified phase) |
0.6972 | Remote Similarity | NPD7914 | Suspended |
0.6961 | Remote Similarity | NPD1454 | Phase 3 |
0.6961 | Remote Similarity | NPD1455 | Phase 3 |
0.6937 | Remote Similarity | NPD3139 | Phase 3 |
0.6887 | Remote Similarity | NPD1385 | Discontinued |
0.6882 | Remote Similarity | NPD9573 | Phase 2 |
0.6863 | Remote Similarity | NPD5789 | Clinical (unspecified phase) |
0.68 | Remote Similarity | NPD215 | Discontinued |
0.6742 | Remote Similarity | NPD9653 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD9555 | Phase 2 |
0.6667 | Remote Similarity | NPD9429 | Discontinued |
0.6636 | Remote Similarity | NPD6946 | Approved |
0.6593 | Remote Similarity | NPD9407 | Approved |
0.6542 | Remote Similarity | NPD2633 | Phase 1 |
0.6538 | Remote Similarity | NPD192 | Phase 2 |
0.65 | Remote Similarity | NPD500 | Discontinued |
0.6486 | Remote Similarity | NPD1805 | Phase 2 |
0.6486 | Remote Similarity | NPD1804 | Phase 2 |
0.6422 | Remote Similarity | NPD1428 | Phase 2 |
0.64 | Remote Similarity | NPD1331 | Approved |
0.6389 | Remote Similarity | NPD4743 | Phase 2 |
0.6354 | Remote Similarity | NPD2691 | Clinical (unspecified phase) |
0.6306 | Remote Similarity | NPD6693 | Phase 3 |
0.6279 | Remote Similarity | NPD9503 | Approved |
0.6279 | Remote Similarity | NPD9504 | Approved |
0.6264 | Remote Similarity | NPD9405 | Approved |
0.6226 | Remote Similarity | NPD3121 | Phase 2 |
0.6154 | Remote Similarity | NPD6936 | Clinical (unspecified phase) |
0.6154 | Remote Similarity | NPD6935 | Phase 3 |
0.6117 | Remote Similarity | NPD285 | Discontinued |
0.6017 | Remote Similarity | NPD7992 | Clinical (unspecified phase) |
0.6 | Remote Similarity | NPD1706 | Clinical (unspecified phase) |
0.5966 | Remote Similarity | NPD7756 | Clinical (unspecified phase) |
0.59 | Remote Similarity | NPD205 | Approved |
0.5872 | Remote Similarity | NPD765 | Discontinued |
0.5789 | Remote Similarity | NPD7761 | Suspended |
0.5729 | Remote Similarity | NPD9370 | Approved |
0.5714 | Remote Similarity | NPD244 | Clinical (unspecified phase) |
0.5714 | Remote Similarity | NPD9427 | Approved |
0.5714 | Remote Similarity | NPD9369 | Clinical (unspecified phase) |
0.5702 | Remote Similarity | NPD6918 | Phase 1 |
0.5648 | Remote Similarity | NPD6948 | Phase 3 |
0.5612 | Remote Similarity | NPD9372 | Phase 2 |
PubChem CID   | 3954028 |
ChEMBL   | CHEMBL1330220 |
ZINC   |
Molecular Weight:   | 260.05 |
ALogP:   | -1.9192 |
MLogP:   | 1.57 |
XLogP:   | -1.368 |
# Rotatable Bonds:   | 6 |
Polar Surface Area:   | 141.39 |
# H-Bond Aceptor:   | 7 |
# H-Bond Donor:   | 3 |
# Rings:   | 2 |
# Heavy Atoms:   | 17 |